Coming December: ASH publishes its late-breaking abstracts. We’ll add the organizations presenting them.

Biotech companies at ASH 2026

Dec 12–15, 2026 New Orleans, LA ~30k attendees Website

135 biotech companies are at ASH 2026 — 132 presentations on the program and 57 with a booth in the exhibit hall. Most represented: Qihan Biotechnology (6 on the program), Incyte (5 on the program), BeOne Medicines (3 on the program). 64 of them have their own page in this guide. As of Nov 10, 2026.

All 1,934 organizations at ASH 2026 →

Topic
Top represented
Showing 1–6 of 135 organizations
OrganizationASH 2026 Attendance
QB
Qihan Biotechnology
Hangzhou, China
Biotech
Biotechnology company developing cell and gene therapies in Hangzhou, China.
Incyte
Wilmington, DE
Biotech
Biopharmaceutical company discovering, developing and marketing its own medicines in oncology and in inflammation and autoimmunity.
Booth
Exhibiting at Booth 228, 1113
Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm
Symposium
Fri Dec 11
3:00pm–6:00pm
A Case-Based Exploration of Current and Future Directions in Myelofibrosis – Where We Are, Where We’re Going
Real patient cases showing how experts treat myelofibrosis today, paired with reviews of current data and ongoing research on emerging therapies.
Leukemias
Symposium
Fri Dec 11
7:00pm–10:00pm
Addressing Community Oncologists’ Questions About Novel Therapies in Non-Hodgkin Lymphoma – What Clinicians Want To Know
Answers to community oncologists' most pressing questions about new drugs for non-Hodgkin lymphoma, drawn from a survey and reviewed against current research.
Lymphoma
BeOne Medicines
Basel, Switzerland
Biotech
Global oncology company, formerly BeiGene, whose medicines include the BTK inhibitor zanubrutinib for CLL and other B-cell cancers.
Booth
Exhibiting at Booth 421
Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm
Symposium
Fri Dec 11
7:00am–10:00am
Consensus or Controversy? Documenting And Discussing Investigators’ Approaches to the Management of Patients with Chronic Lymphocytic Leukemia
How clinical investigators differ on managing chronic lymphocytic leukemia, comparing their answers on hard cases alongside current data and ongoing research.
Lymphoma
Symposium
Fri Dec 11
11:00am–2:00pm
CLL Challenge! Interrogating the Latest Evidence on Patient Priorities and Novel Targeted Therapies
Shared decision-making in chronic lymphocytic leukemia, using biomarker testing to choose among fixed-duration, continuous, and newer targeted treatments.
Symposium hosted by Decera Clinical Education
Lymphoma
Symposium
Fri Dec 11
11:00am–2:00pm
Realigning Modern Care in MCL: Guidance on the Next Wave of Advances With BTK Inhibitor Options and New Targeted Strategies
Mantle cell lymphoma care built on Bruton tyrosine kinase inhibitors up front, with newer kinase and Bcl-2 inhibitors or CAR-T after relapse.
Symposium hosted by PeerView Institute for Medical Education
Lymphoma · New drugs
Symposium
Fri Dec 11
7:00pm–10:00pm
Addressing Community Oncologists’ Questions About Novel Therapies in Non-Hodgkin Lymphoma – What Clinicians Want To Know
Answers to community oncologists' most pressing questions about new drugs for non-Hodgkin lymphoma, drawn from a survey and reviewed against current research.
Lymphoma
Genmab
Copenhagen, Denmark
Biotech
Danish antibody company developing bispecific antibodies and antibody-drug conjugates, including epcoritamab for lymphoma.
Booth
Exhibiting at Booth 3229
Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm
Symposium
Fri Dec 11
11:00am–2:00pm
Best Practice Use of Bispecific Antibodies in Non-Hodgkin Lymphoma – A Second Opinion Case Review
Difficult non-Hodgkin lymphoma cases treated or considered for bispecific antibodies, with reviews of recent data, current practice, and ongoing trials.
Lymphoma · New drugs
Symposium
Fri Dec 11
11:00am–2:00pm
Bispecific Antibodies in Action: Applying Evidence Across the DLBCL and FL Care Continuum
Bispecific antibodies in relapsed diffuse large B-cell and follicular lymphoma, from sequencing with CAR-T to outpatient step-up dosing and side effects.
Symposium hosted by PRIME Education
Lymphoma · New drugs
Symposium
Fri Dec 11
3:00pm–6:00pm
Optimizing Integration of BsAb-Based Therapies for FL and DLBCL: Expert Perspectives on New Standards and Future Directions
How bispecific antibodies for follicular and diffuse large B-cell lymphoma differ in structure, dosing, and safety, and how to sequence them in community care.
Symposium hosted by Decera Clinical Education
Lymphoma · New drugs
Tessera Therapeutics
Somerville, MA
Biotech
Biotechnology company developing genetic medicines using gene writing.
Biotech
Commercial-stage biotech with a menin inhibitor for relapsed or refractory acute leukemia and a CSF-1 receptor antibody for chronic GVHD.
Booth
Exhibiting at Booth 3539
Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm
Symposium
Fri Dec 11
11:00am–2:00pm
Medical Crossfire®: Precision Decisions in AML – Experts Debating Frontline Therapy, Targeted Agents, and Sequencing Across Care
Frontline therapy, targeted drugs, and treatment sequencing in acute myeloid leukemia, framed around real questions from community oncologists.
Leukemias

Explore the full ASH 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in New Orleans. Leave your work email and we’ll be in touch.

Privacy

Download the full ASH 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find buyers from biotech companies

Tell us what you sell and we’ll find the people at these biotech companies most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Browse ASH 2026 by

Exhibit hall

Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction